Wave Life Sciences Shares Up on 4Q Revenue Beat, 2025 Momentum

Dow Jones

2025/03/05

By Adriano Marchese

Shares of Wave Life Sciences rose Tuesday after reporting that its revenue more than doubled, topping expectations, and a profit for the fourth quarter.

Shares traded 9.8% higher at $11.03.

The RNA-focused biotechnology company reported revenue of $83.7 million for the fourth quarter compared with $29.1 million in the prior-year period, and topping analyst expectations of $28.7 million, according to FactSet.

Net income was $29.3 million, compared with a loss of $16.3 million. On a per-share basis, this was 17 cents profit, up from a loss of 15 cents.

Chief Executive Paul Bolno said 2024 was an exceptional year for the company and that the positive momentum has continued so far into 2025.

"With both our progress in the clinic and in advancing a broad pipeline targeting high-impact biology, we are building a leading RNA medicines company," Bolno said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

March 04, 2025 12:33 ET (17:33 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2517604286"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517604286\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2517604286?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-05 01:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517604286","market":"fut","top_or_hot":-1,"title":"Wave Life Sciences Shares Up on 4Q Revenue Beat, 2025 Momentum","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Wave Life Sciences rose Tuesday after reporting that its revenue more than doubled, topping expectations, and a profit for the fourth quarter. \n</p>\n<p>\n  Shares traded 9.8% higher at $11.03. \n</p>\n<p>\n  The RNA-focused biotechnology company reported revenue of $83.7 million for the fourth quarter compared with $29.1 million in the prior-year period, and topping analyst expectations of $28.7 million, according to FactSet. \n</p>\n<p>\n  Net income was $29.3 million, compared with a loss of $16.3 million. On a per-share basis, this was 17 cents profit, up from a loss of 15 cents. \n</p>\n<p>\n  Chief Executive Paul Bolno said 2024 was an exceptional year for the company and that the positive momentum has continued so far into 2025. \n</p>\n<p>\n  \"With both our progress in the clinic and in advancing a broad pipeline targeting high-impact biology, we are building a leading RNA medicines company,\" Bolno said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 04, 2025 12:33 ET (17:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wave Life Sciences Shares Up on 4Q Revenue Beat, 2025 Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWave Life Sciences Shares Up on 4Q Revenue Beat, 2025 Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-05 01:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Wave Life Sciences rose Tuesday after reporting that its revenue more than doubled, topping expectations, and a profit for the fourth quarter. \n</p>\n<p>\n  Shares traded 9.8% higher at $11.03. \n</p>\n<p>\n  The RNA-focused biotechnology company reported revenue of $83.7 million for the fourth quarter compared with $29.1 million in the prior-year period, and topping analyst expectations of $28.7 million, according to FactSet. \n</p>\n<p>\n  Net income was $29.3 million, compared with a loss of $16.3 million. On a per-share basis, this was 17 cents profit, up from a loss of 15 cents. \n</p>\n<p>\n  Chief Executive Paul Bolno said 2024 was an exceptional year for the company and that the positive momentum has continued so far into 2025. \n</p>\n<p>\n  \"With both our progress in the clinic and in advancing a broad pipeline targeting high-impact biology, we are building a leading RNA medicines company,\" Bolno said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 04, 2025 12:33 ET (17:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WVE","symbol_name":"Wave Life Sciences Pte. Ltd","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2517604286","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517604286","pubTimestamp":1741109580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Wave Life Sciences rose Tuesday after reporting that its revenue more than doubled, topping expectations, and a profit for the fourth quarter.The RNA-focused biotechnology company reported revenue of $83.7 million for the fourth quarter compared with $29.1 million in the prior-year period, and topping analyst expectations of $28.7 million, according to FactSet.Net income was $29.3 million, compared with a loss of $16.3 million. On a per-share basis, this was 17 cents profit, up from a loss of 15 cents.Chief Executive Paul Bolno said 2024 was an exceptional year for the company and that the positive momentum has continued so far into 2025.\"With both our progress in the clinic and in advancing a broad pipeline targeting high-impact biology, we are building a leading RNA medicines company,\" Bolno said.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"WVE":"Wave Life Sciences Pte. Ltd"},"translate_title":"Wave Life Sciences股价因第四季度收入超出预期和2025年势头而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WVE":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Shares of Wave Life Sciences rose Tuesday after reporting that its revenue more than doubled, topping expectations, and a profit for the fourth quarter. \n\n\n  Shares traded 9.8% higher at $11.03. \n\n\n  The RNA-focused biotechnology company reported revenue of $83.7 million for the fourth quarter compared with $29.1 million in the prior-year period, and topping analyst expectations of $28.7 million, according to FactSet. \n\n\n  Net income was $29.3 million, compared with a loss of $16.3 million. On a per-share basis, this was 17 cents profit, up from a loss of 15 cents. \n\n\n  Chief Executive Paul Bolno said 2024 was an exceptional year for the company and that the positive momentum has continued so far into 2025. \n\n\n  \"With both our progress in the clinic and in advancing a broad pipeline targeting high-impact biology, we are building a leading RNA medicines company,\" Bolno said. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2025 12:33 ET (17:33 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}